Mark Daniel

Mark Daniel is a Board Member of National Fiduciary Trust and Chair of the Board’s Audit Committee. He plays a key role in guiding the organization’s long-term direction and ensuring strong governance across all aspects of trust administration. Mr. Daniel is a seasoned finance executive with more than 25 years of experience providing strategic, financial, and governance leadership to complex organizations. As a Director with National Fiduciary Trust, Inc., he brings deep expertise in financial oversight, capital stewardship, risk management, and organizational transformation. Throughout his career, Mr. Daniel has guided companies through periods of growth, strategic transactions, and operational enhancement, consistently strengthening financial controls, reporting integrity, and long-term value creation.

In addition to his role with NFT, Mr. Daniel currently serves as the Chief Financial Officer for Atossa Therapeutics, Inc., a Seattle based therapeutics company focused on providing therapeutic solutions for breast cancer and other rare disease conditions with significant unmet need. Prior to his current role, Mr. Daniel held senior finance and accounting leadership roles with Bruker Spatial Biology, a subsidiary of Bruker Corporation (formerly NanoString Technologies, Ind.) HaloSource, Cardiac Science, and Numera (Newyu), overseeing SEC reporting, global finance operations, and efficiency initiatives. Mr. Daniel began his career with KPMG’s assurance practice. He holds a Bachelor of Science in Business Administration from Washington State University and is a Certified Public Accountant (Washington State, inactive).